CAMP4 THERAPEUTICS CORP (CAMP) Stock Price, Quote, News and Overview
NASDAQ:CAMP - Nasdaq - US13463J1016 - Common Stock - Currency: USD
CAMP Quote, Performance and Key Statistics
1.58
-0.07 (-4.24%)
The current stock price of CAMP is 1.58 USD. In the past month the price decreased by -15.05%. In the past year, price decreased by -56.23%.
CAMP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.74 | 339.89B | ||
| AMGN | AMGEN INC | 14.32 | 159.86B | ||
| GILD | GILEAD SCIENCES INC | 14.48 | 139.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.78 | 56.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.73B | ||
| ARGX | ARGENX SE - ADR | 102.05 | 35.83B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.08 | 29.91B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.22B | ||
| NTRA | NATERA INC | N/A | 22.44B | ||
| BIIB | BIOGEN INC | 8.36 | 19.39B | ||
| INSM | INSMED INC | N/A | 17.65B |
Related stock screener links
About CAMP
Company Profile
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company is headquartered in Cambridge, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-10-11. The firm is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. The company is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
Company Info
CAMP4 THERAPEUTICS CORP
One Kendall Square, Bldg 1400 West 3rd Floor
Cambridge MASSACHUSETTS 92618 US
CEO: Jeffery Gardner
Employees: 644
Phone: 16176518867
CAMP4 THERAPEUTICS CORP / CAMP FAQ
What is the stock price of CAMP4 THERAPEUTICS CORP today?
The current stock price of CAMP is 1.58 USD. The price decreased by -4.24% in the last trading session.
What is the ticker symbol for CAMP4 THERAPEUTICS CORP stock?
The exchange symbol of CAMP4 THERAPEUTICS CORP is CAMP and it is listed on the Nasdaq exchange.
On which exchange is CAMP stock listed?
CAMP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CAMP4 THERAPEUTICS CORP stock?
11 analysts have analysed CAMP and the average price target is 16.58 USD. This implies a price increase of 949.05% is expected in the next year compared to the current price of 1.58. Check the CAMP4 THERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CAMP4 THERAPEUTICS CORP worth?
CAMP4 THERAPEUTICS CORP (CAMP) has a market capitalization of 31.85M USD. This makes CAMP a Nano Cap stock.
How many employees does CAMP4 THERAPEUTICS CORP have?
CAMP4 THERAPEUTICS CORP (CAMP) currently has 644 employees.
What are the support and resistance levels for CAMP4 THERAPEUTICS CORP (CAMP) stock?
CAMP4 THERAPEUTICS CORP (CAMP) has a resistance level at 1.88. Check the full technical report for a detailed analysis of CAMP support and resistance levels.
Is CAMP4 THERAPEUTICS CORP (CAMP) expected to grow?
The Revenue of CAMP4 THERAPEUTICS CORP (CAMP) is expected to grow by 855.38% in the next year. Check the estimates tab for more information on the CAMP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CAMP4 THERAPEUTICS CORP (CAMP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CAMP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CAMP, evaluating the profitability, health, valuation and growth aspects
- CAMP4 THERAPEUTICS CORP (CAMP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CAMP4 THERAPEUTICS CORP (CAMP) Sales and EPS estimates to see what analysts future expectations are.
- CAMP4 THERAPEUTICS CORP (CAMP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CAMP4 THERAPEUTICS CORP (CAMP) Insider and Institutional Ownership to learn about the owners and their transactions.
- CAMP4 THERAPEUTICS CORP (CAMP) Stock Chart to make your own analysis
- CAMP4 THERAPEUTICS CORP (CAMP) Latest news and press-releases to stay up to date.
Does CAMP4 THERAPEUTICS CORP (CAMP) stock pay dividends?
CAMP does not pay a dividend.
What is the Price/Earnings (PE) ratio of CAMP4 THERAPEUTICS CORP (CAMP)?
CAMP4 THERAPEUTICS CORP (CAMP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-27.87).
What is the Short Interest ratio of CAMP4 THERAPEUTICS CORP (CAMP) stock?
The outstanding short interest for CAMP4 THERAPEUTICS CORP (CAMP) is 4.08% of its float. Check the ownership tab for more information on the CAMP short interest.
CAMP Technical Analysis
CAMP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CAMP. CAMP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CAMP Financial Highlights
Over the last trailing twelve months CAMP reported a non-GAAP Earnings per Share(EPS) of -27.87. The EPS decreased by -1852.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -100% | ||
| ROE | -121.15% | ||
| Debt/Equity | 0 |
CAMP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to CAMP. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 51.57% and a revenue growth 855.38% for CAMP